faqs on bmca-targeted bispecific antibodies in multiple myeloma
Published 1 year ago • 289 plays • Length 30:24Download video MP4
Download video MP3
Similar videos
-
41:37
faqs on non-bcma-targeted bispecific antibodies in multiple myeloma
-
52:51
faqs on bispecific antibodies in multiple myeloma
-
6:09
bispecific antibodies | high impact topic (hit)
-
23:13
bispecific antibodies in multiple myeloma | dana-farber cancer institute
-
7:06
efficacy and safety of elranatamab bcma-cd3 bispecific antibody, in patients with rrmm
-
0:41
fcrh5 & gprc5d bispecific antibodies: antigen targets beyond bcma for multiple myeloma
-
4:15
bispecific antibodies in multiple myeloma: teclistamab, talquetamab, and cevostamab
-
3:28
the importance of bcma-targeting adcs and bispecific antibodies in r/r multiple myeloma
-
1:20
a comparison of bispecific antibodies emerging in multiple myeloma
-
9:57
teclistamab, a bcma × cd3 bispecific antibody, in pts with rrmm: updated phase 1 results
-
57:20
know your myeloma immunotherapy: bispecific antibodies with dr. cesar rodriguez
-
7:25
updated phase 1 results of teclistamab, a bcma × cd3 bispecific antibody, in rrmm
-
2:33
an update on antibody-based treatment approaches in multiple myeloma
-
1:23
targeting bcma with bispecific antibodies in r/r myeloma
-
1:53
infections following anti-bcma bispecific antibodies for multiple myeloma
-
58:40
faqs on biomarkers in multiple myeloma
-
3:25
what should myeloma patients know about bispecific antibodies?
-
1:25
dr. morgan on bcma-targeted adcs in multiple myeloma
-
1:14
phase i study of abbv-383, a bcma×cd3 bispecific antibody, in r/r myeloma